



## LJMU Research Online

**Bakker, EA, Snoek, JA, Meindersma, EP, Hopman, MTE, Bellersen, L, Verbeek, ALM, Thijssen, DHJ and Eijsvogels, TMH**

**Absence of Fitness Improvement Is Associated with Outcomes in Heart Failure Patients.**

<http://researchonline.ljmu.ac.uk/id/eprint/7245/>

### Article

**Citation** (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

**Bakker, EA, Snoek, JA, Meindersma, EP, Hopman, MTE, Bellersen, L, Verbeek, ALM, Thijssen, DHJ and Eijsvogels, TMH (2017) Absence of Fitness Improvement Is Associated with Outcomes in Heart Failure Patients. Medicine and Science in Sports and Exercise. ISSN 1530-0315**

LJMU has developed [LJMU Research Online](http://researchonline.ljmu.ac.uk/) for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact [researchonline@ljmu.ac.uk](mailto:researchonline@ljmu.ac.uk)

<http://researchonline.ljmu.ac.uk/>

1 **Absence of Fitness Improvement Is Associated with Outcomes in Heart Failure Patients**

2

3 Esmée A. Bakker, MSc<sup>1,5</sup>

4 Johan A. Snoek, MD<sup>4</sup>

5 Esther P. Meindersma, MD<sup>3,4</sup>

6 Maria T.E. Hopman, MD, PhD<sup>1</sup>

7 Louise Bellersen, MD<sup>3</sup>

8 André L.M. Verbeek, MD, PhD<sup>2</sup>

9 Dick H.J. Thijssen, PhD<sup>1,5</sup>

10 Thijs M.H. Eijsvogels, PhD<sup>1,5</sup>

11

12 **Word count text:** 3241

13 **Word count abstract:** 269

14 **Tables:** 1

15 **Figures:** 4

16

17 **Affiliations**

18 Radboud Institute for Health Sciences, departments of <sup>1</sup>Physiology, <sup>2</sup>Health Evidence and

19 <sup>3</sup>Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.

20 <sup>4</sup>Heart Centre, Isala, Zwolle, The Netherlands. <sup>5</sup>Research Institute for Sports and Exercise

21 Sciences, Liverpool John Moores University, Liverpool, United Kingdom.

22 **Address for correspondence**

23 Esmée Bakker, MSc, Dept. of Physiology (392), Radboud University Medical Center,

24 P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.

25 E-mail: [Esmee.Bakker@radboudumc.nl](mailto:Esmee.Bakker@radboudumc.nl)

26 Tel. (+31) (0)24 36 14906 Fax. (+31) (0)24 36 68340

27 **Abstract**

28 **Purpose.** To examine the clinical impact of cardiorespiratory fitness (CRF) and  
29 improvements in CRF after cardiac rehabilitation (CR) in heart failure (HF) patients for their  
30 risk of all-cause mortality and unplanned hospitalization. Secondly, to investigate possible  
31 factors associated with the absence of improvement in CRF after rehabilitation.

32 **Methods.** We included 155 HF patients receiving CR between October 2009 and January  
33 2015. Patients performed an incremental bicycle test to assess CRF through peak oxygen  
34 uptake (VO<sub>2</sub>-peak) before and after CR-based supervised exercise training. Patients were  
35 classified as responders or non-responders based on pre-to-post CR changes in VO<sub>2</sub>-peak  
36 ( $\geq 6\%$  and  $< 6\%$ , respectively). Cox proportional hazards models evaluated all-cause mortality  
37 and unplanned hospitalization during 5 years of follow-up. Patient characteristics, HF features  
38 and co-morbidities were used to predict changes in VO<sub>2</sub>-peak using logistic regression  
39 analysis.

40 **Results.** Seventy HF patients (45%) were classified as responder. Non-responders had a  
41 significantly higher risk of all-cause mortality or hospitalization (HR = 2.15, 95% CI = 1.17-  
42 3.94) compared to responders. This was even higher in non-responders with low CRF at  
43 baseline (HR = 4.88, 95% CI = 1.71-13.93). Factors associated with non-response to CR were  
44 age (OR = 1.07/year, 95% CI = 1.03-1.11), baseline VO<sub>2</sub>-peak (OR = 1.16/ml/min/kg, 95%  
45 CI = 1.06-1.26) and adherence to CR (OR = 0.98/percentage, 95% CI = 0.96-0.998).

46 **Conclusion.** Independent from baseline CRF, the inability to improve VO<sub>2</sub>-peak by CR  
47 doubled the risk of death or unplanned hospitalization. The combination of lower baseline  
48 CRF and non-response was associated with even poorer clinical outcomes. Especially older  
49 HF patients with higher baseline VO<sub>2</sub>-peak and lower adherence have a higher probability of  
50 becoming a non-responder.

51 **Key words:** exercise, cardiovascular risk, morbidity/mortality, physical fitness, unplanned  
52 hospitalization

53 **INTRODUCTION**

54 Heart failure (HF) is diagnosed in 1-2% of the adult population of developed countries and is  
55 characterized by a structural or functional impairment of ventricular filling or ejection (1, 2).  
56 HF patients typically suffer from dyspnea and fatigue, which may limit their habitual physical  
57 activity and contribute to exercise intolerance. Hence, the cardiorespiratory fitness (CRF) of  
58 HF patients is lower compared to age- and sex-predicted reference values (3, 4). Previous  
59 studies indicated that CRF is an important predictor for the course of disease (5, 6), with  
60 lower CRF being related to an increased risk of cardiovascular events. Improvement of CRF  
61 through exercise training is therefore recommended in HF patients (1, 2).

62 Previous studies in HF patients suggest a potential decline in mortality and  
63 hospitalization rate after standardized cardiac rehabilitation (CR; involving exercise training)  
64 compared to usual care (7, 8). However, significant heterogeneity exists in individual  
65 responses to CR, with some demonstrating no change or even a decline in fitness. It has been  
66 estimated that only half of the HF patients improve their fitness after standardized CR (9, 10),  
67 compared to 86% in non-HF individuals (11). Evidence is limited whether the absence of  
68 improvement affects future survival and morbidity. Preliminary work suggests that HF  
69 patients with an increased fitness after CR (*responders*) have a lower risk of all-cause  
70 mortality and hospitalization compared to patients without such improvements (*non-*  
71 *responders*) (9). Likewise, non-responders demonstrated an increased risk of cardiac events  
72 compared to responders (10). These studies were, however, limited by a low adherence (40%)  
73 to the exercise training sessions. Moreover, the work related to a specific population of HF  
74 patients (i.e. young (systolic) HF patients) and relatively short follow-up (9, 10). Given the  
75 overall health benefits of CR-based exercise programs and the high number of non-  
76 responders, it is relevant to better understand the clinical impact of being a non-responder and  
77 to identify HF patients who are at particular risk of becoming a non-responder.

78           Therefore, the aim of our study was to compare the risk of morbidity and all-cause  
79 mortality between HF patients responding and non-responding in CRF improvement after  
80 standardized and supervised exercise training as part of a CR program. We expect that  
81 improvement in CRF after rehabilitation is associated with a reduced risk of morbidity and all-  
82 cause mortality, whilst this observation is independent of pre-rehabilitation levels of CRF.  
83 Furthermore, to better understand the characteristics of a non-responder, we aimed to predict  
84 which HF patients will become a non-responder to CR using personal-, health-, disease- and  
85 exercise training-related characteristics.

86

## 87 **METHODS**

### 88 *Subjects*

89 All HF patients who followed supervised exercise training as part of a CR program at the  
90 Radboud university medical center or Isala Clinic between October 2009 and January 2015  
91 were eligible for participation in the study. Both patients with a reduced ejection fraction  
92 (HFrEF) and a preserved ejection fraction (HFprEF) were included if they performed a  
93 baseline and follow-up fitness test. HF patients with a peak respiratory exchange ratio (RER)  
94 <1.00 at baseline and/or post-training exercise test were excluded from the study to guarantee  
95 the quality of the included data.

96

### 97 *Experimental design*

98 At baseline and after completion of the exercise-training program, HF patients underwent  
99 cardiopulmonary exercise testing to determine changes in CRF. Absolute change in physical  
100 fitness was assessed by calculation of the difference in peak oxygen uptake (VO<sub>2</sub>-peak)  
101 between both exercise tests. Relative change was calculated by dividing the absolute change  
102 by the baseline VO<sub>2</sub>-peak. HF patients were classified as responder if they demonstrated a

103 relative improvement in  $\text{VO}_2\text{-peak} \geq 6\%$  and as non-responder if the increase in  $\text{VO}_2\text{-peak}$  was  
104  $< 6\%$ . The threshold of 6% improvement was used to compensate for inter-test variability, and  
105 an increase of  $\text{VO}_2\text{-peak} \geq 6\%$  was considered as a meaningful and reliable difference (12).

106 Data related to patient characteristics, unplanned hospitalization and all-cause  
107 mortality were extracted from electronic patient files at both hospitals. The Local Committee  
108 on Research Involving Human Subjects of the region Arnhem and Nijmegen approved the  
109 study, and the study adhered to the Declaration of Helsinki.

110

### 111 *Exercise training programs*

112 HF patients participated in four different supervised exercise-training programs, depending on  
113 year of participation and the available program at the medical center. Patients from the  
114 Radboud university medical center participated in: 1) an 8-week exercise program, consisting  
115 of 2 sessions/week at a moderate exercise intensity (n=23); or 2) a 12- week exercise  
116 program, consisting of 2 sessions/week at moderate (n=10) or high exercise intensity (n=10).  
117 Patients from the Isala Clinic participated in 3) a 12-week exercise program, consisting of 2  
118 sessions/week at a moderate exercise intensity (n=36); or 4) a 24-week exercise program  
119 (n=76), consisting of 2 sessions/week at a moderate exercise intensity. Moderate intensity was  
120 defined as BORG score 11-15. During high intensity training sessions 10 bouts of 1-minute at  
121 90% of the maximal workload were alternated by 2.5 minutes at 30% of the maximal  
122 workload. Adherence of HF patients to the exercise program was defined as the total number  
123 of training sessions performed by a patient divided by the total number of training sessions in  
124 the program. This ratio was multiplied by 100 to obtain a percentage.

125

126

127



128 *Cardiopulmonary exercise test*

129 Standardized exercise testing was performed on a bicycle ergometer with increasing workload  
130 until exhaustion. The oxygen consumption was measured by an automated system, which was  
131 calibrated before every test with both ambient air and a fixed known gas mixture. During  
132 exercise testing, subjects were verbally encouraged to achieve maximum exertion, evidenced  
133 by a RER  $\geq 1.00$ . Respiratory gas analysis measured the oxygen uptake, carbon dioxide  
134 production, and ventilation. Gas exchange results were used to determine the  $\text{VO}_2$ -peak,  
135 which was defined as the average  $\text{VO}_2$  over the last 30 seconds of the exercise test. The  
136 maximum heart rate and workload (Watt) were measured during the exercise test.

137

138 *Data extraction*

139 Electronic patient files were used to collect: 1) baseline patient characteristics including age,  
140 sex, body mass index (BMI), current smoking status and co-morbidities (diabetes mellitus,  
141 chronic obstructive pulmonary disease and hypertension), and 2) HF characteristics such as  
142 disease etiology (ischemic *versus* non-ischemic), New York Heart Association (NYHA)  
143 classification, left ventricular ejection fraction, history of atrium fibrillation, medication use  
144 (angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, beta blocker agent,  
145 aldosterone receptor antagonist, loop diuretic and statins), and the presence of medical  
146 devices (pacemaker, cardiac resynchronization therapy or implantable cardioverter  
147 defibrillator). Furthermore, we used all-cause unplanned hospitalization events and all-cause  
148 mortality as our end points and obtained these from the electronic patient files.

149

150 *Data analysis*

151 Kaplan–Meier curves and the log-rank test were used to assess the difference in clinical  
152 outcome between responders and non-responders. The end-point was any unplanned

153 hospitalization or all-cause mortality. Patients who did not reach the end-point were censored  
154 at the end of the observation period or after 5 years of follow-up. The follow-up started at the  
155 baseline cardiopulmonary exercise test prior to CR. The crude hazard rate ratio (HR) with  
156 95% confidence interval (CI) was calculated first by univariable Cox proportional hazards  
157 modelling. Subsequently, we compared patient characteristics, HF characteristics, medication  
158 use, medical devices and physiological variables between groups using the chi-squared test  
159 for categorical variables, Student's t-test for normally distributed continuous variables and the  
160 Mann-Whitney U test for not normally distributed continuous variables. We adjusted the  
161 survival analysis with multivariable Cox proportional hazards modelling for the following  
162 possible confounding factors: age, sex, BMI, baseline VO<sub>2</sub>-peak and a cardiac  
163 resynchronization therapy combined with implantable cardioverter defibrillator. The adjusted  
164 HR was calculated with a 95% CI.

165         To calculate the odds of becoming a non-responder, we used univariable logistic  
166 regression and examined the following factors: age, sex, BMI, current smoking status, co-  
167 morbidities, disease etiology, NYHA classification, ejection fraction, history of atrium  
168 fibrillation, medication use and the presence of medical devices (pacemakers, cardiac  
169 resynchronization therapy or implantable cardioverter defibrillator), adherence, duration and  
170 type of the rehabilitation program, and baseline values of VO<sub>2</sub>-peak, maximum achieved heart  
171 rate and peak workload. The potential factors were entered into a hierarchical multivariable  
172 logistic regression model using different blocks. In all blocks, backward selection was used  
173 with stepwise removal at  $P = 0.10$  to identify the most predictive variables. The  
174 discriminative performance of the model was assessed by calculating the area under the  
175 receiver operating characteristic curve (AUC).

176         To calculate the necessary sample size, we performed a power calculation using a  
177 power of 80%, an overall type 1 error of 0.05 (two-sided), and as clinically relevant effect size

178 a hazard ratio of 2. Approximately 145 subjects were needed to obtain the number of required  
179 events (n=71)(13). To develop a prediction model, we use the rule of thumb with minimal 10  
180 events per variable for obtaining a good prediction(14, 15). Statistical analyses were  
181 performed in SPSS 20.0. A  $P < 0.05$  was considered statistically significant.

182

## 183 **RESULTS**

### 184 *Study population*

185 A total of 187 HF patients met the inclusion criteria of our study. After inspection for data  
186 quality, 32 patients were excluded due to a maximum RER<1.00 during the maximal exercise  
187 test. As a result 155 patients were available for analysis (Figure 1), with a median adherence  
188 to the supervised training sessions of 88% and inter-quartile range of 79%–96%.

189

### 190 *Responders versus non-responders*

191 Seventy HF patients (45%) were classified as responder (Supplemental Figure 1). Non-  
192 responders were more frequently men, had a lower adherence to the rehabilitation program, a  
193 higher baseline VO<sub>2</sub>-peak and a lower post-training VO<sub>2</sub>-peak compared to responders (Table  
194 1). Age, BMI, current smoking behavior, and the duration of the rehabilitation program did  
195 not differ between the groups. Likewise, no differences in HF characteristics, co-morbidities,  
196 medication use, medical devices and other physiological data were found.

197

### 198 *All-cause mortality and unplanned hospitalization*

199 143 out of 155 HF patients were included in the survival analysis, as the follow-up data of 12  
200 patients were not accessible for data protection reasons. In total 57 HF patients died or had an  
201 unplanned hospitalization: 36 non-responders (46%) and 21 responders (33%). The median  
202 follow-up period was 23 months (inter-quartile range 13–47) for non-responders and 30

203 months (15–50) for responders. Figure 2 shows the Kaplan-Meier curves for time to  
204 unplanned hospitalization or death ( $P=0.12$ ). Non-responders had a 52% higher risk of death  
205 or unplanned hospitalization than responders (HR = 1.52, 95% CI = 0.89-2.61). The  
206 multivariable Cox proportional hazards regression analysis showed that the risk of death or  
207 unplanned hospitalization was more than twice as high in non-responders (HR = 2.15, 95% CI  
208 = 1.17-3.94) after adjustment for age, sex, BMI, baseline VO<sub>2</sub>-peak and a cardiac  
209 resynchronization therapy combined with implantable cardioverter defibrillator. Subgroup  
210 analyses did not show any difference in results for patients with HFrEF or HFprEF at  
211 baseline.

212 A lower baseline CRF level (VO<sub>2</sub>-peak <16.5 ml/min/kg) was associated with a 2.76  
213 (95% CI = 1.52-5.05) increased risk of all-cause mortality and unplanned hospitalization after  
214 adjustment for age, sex, BMI and response status. Conversely, after adjustment for age, sex,  
215 BMI, and CRF level, non-responders had a 1.80 (95% CI = 1.02-3.18) higher risk of all-cause  
216 mortality and unplanned hospitalization. Non-responders with the lowest baseline CRF had a  
217 4.88 (95% CI = 1.71-13.93) higher risk of all-cause mortality or unplanned hospitalization  
218 compared to responders with a high baseline CRF level (Figure 3).

219

#### 220 *Predicting response to exercise training*

221 We identified age, sex, etiology of HF, use of angiotensin-converting enzyme inhibitor or  
222 angiotensin II receptor blocker, loop diuretics, pacemaker, baseline VO<sub>2</sub>-peak and adherence  
223 to the exercise program as potential factors associated with becoming a non-responder to CR  
224 based exercise training (Supplemental Table 1). Multivariable logistic regression analysis  
225 revealed that HF patients of higher age (odds ratio [OR] = 1.07/year, 95 % CI = 1.03–1.11),  
226 higher baseline VO<sub>2</sub>-peak (OR = 1.16/ml/min/kg, 95% CI = 1.06–1.26) and adherence to the  
227 exercise program (OR = 0.98/percentage, 95% CI = 0.96–0.998) were associated with being a

228 non-responder. The performance of the prediction model is shown in Figure 4 and  
229 demonstrates an AUC of 0.73 (95% CI = 0.65–0.82).

230

## 231 **DISCUSSION**

232 As many as 55% of 155 HF patients did not increase VO<sub>2</sub>-peak following supervised exercise  
233 training sessions in a CR program. More importantly, HF patients classified as non-  
234 responders to CR had a 2.15 times higher risk of all-cause mortality or unplanned  
235 hospitalization compared to responders after adjustment for possible confounders. The  
236 increased risk of all-cause mortality or unplanned hospitalization for non-responders was  
237 independent of pre-rehabilitation CRF levels. In addition, non-responders with lower CRF  
238 levels had the worst prognosis for unplanned hospitalization and all-cause mortality. Taken  
239 together, our data reinforce the clinical importance of baseline CRF levels and the ability to  
240 improve fitness after exercise training. In order to predict non-response to CR, we found that  
241 higher age, lower adherence and higher baseline VO<sub>2</sub>-peak were significant associated with of  
242 non-response status.

243

### 244 *Non-response, all-cause mortality and unplanned hospitalization*

245 We found that 85 HF patients (55% of study population) were classified as non-responders to  
246 exercise training. Although this prevalence is remarkably high, our findings are in line with  
247 most (50-56% non-responders) (9, 10), but not all (0.9% non-responders) (16), studies  
248 assessing changes in VO<sub>2</sub>-peak following CR. The conflicting outcomes are probably related  
249 to the definition of being a non-responder. For example, the study of Leifer et al. with a  
250 prevalence of 0.9% non-responders defined non-response as a decrease in VO<sub>2</sub>-peak  $\geq$ 5  
251 ml/min/kg (16), whereas we and others (9, 10) defined non-response as a lack of increase in  
252 VO<sub>2</sub>-peak after exercise training. Nonetheless, our data provides further evidence that the

253 presence of non-responders in HF patients who participate in CR programs is larger than  
254 typically observed in a healthy patient cohort.

255 In line with our observations, previous work found that HF patients benefit from  
256 exercise training (7, 17-19). Data from the HF-ACTION trial revealed a 5% higher risk for  
257 all-cause mortality or all-cause hospitalization in non-responders compared to responders  
258 after 3 years of follow-up (9). The benefits of VO<sub>2</sub>-peak improvement were much larger in  
259 our study population as we found a 2.15 higher risk (HR = 2.15, 95% CI = 1.17–3.94) for all-  
260 cause mortality or unplanned hospitalization in non-responders versus responders after 5 years  
261 of follow-up. However, comparison between the HF-ACTION trial and this study is limited  
262 since HF-ACTION only included HF<sub>r</sub>EF patients and this study included both HF<sub>r</sub>EF and  
263 HF<sub>pr</sub>EF. In addition, apart from a longer follow-up time, the difference in risk reduction  
264 between our study and HF-ACTION may also relate to study cohort characteristics.  
265 Compared to the HF-ACTION trial, our HF patients were more often classified as NYHA  
266 classification I or II, showed a lower prevalence of ischemic etiology, a higher baseline peak-  
267 VO<sub>2</sub> (16.5 versus 15.0 ml/min/kg), and had a relatively high adherence (median, 88%). These  
268 factors (i.e. lower NYHA classification, non-ischemic etiology (20), higher CRF (6)) are  
269 typically associated with better survival in HF patients. This suggests that less severe HF  
270 patients may have greater health benefits from CRF improvements following CR. Future  
271 studies are required to better understand this relation.

272

273 In examining the benefits of cardiac rehabilitation it is important to take pre-  
274 rehabilitation levels of fitness into consideration since previous work found that fitness may  
275 represent the strongest predictor for (all-cause) mortality and morbidity in HF patients (5, 6).  
276 In agreement with this previous research, we found that baseline fitness levels are strongly  
277 and independently related to mortality or hospitalization. Taking both baseline fitness and

278 change in fitness post-rehabilitation into consideration, we found that non-responders with  
279 lower fitness levels had the highest risk of adverse clinical outcomes. These data show for the  
280 first time that, both, lower baseline fitness levels and non-response to CR are independently  
281 and in combination associated with an increased risk of adverse events in HF patients.

282

### 283 *Prediction of non-response*

284 In this study we tried to identify factors that predict non-response to exercise training in HF  
285 patients, since this response is related to future adverse events. We demonstrated that older  
286 HF patients with a relatively high baseline VO<sub>2</sub>-peak and lower adherence were more often  
287 non-responders. These findings align with observations from other studies. A meta-analysis in  
288 HF patients showed that lower age was associated with larger improvements of VO<sub>2</sub>-peak  
289 (21). Also, HF patients higher VO<sub>2</sub>-peak (22, 23) had smaller improvements in fitness  
290 following exercise training. Medication use was not associated with response status and did  
291 not significantly change during CR within both groups. Therefore, we do not expect an  
292 interaction of medication in relation to performance outcomes. Our prediction model had an  
293 AUC of 0.73, which indicates that the discriminative power of our model is not sufficient for  
294 direct implementation in clinical practice. Nonetheless, we have identified factors that  
295 significantly contribute to the prediction whether CRF improves after training. The addition of  
296 chronotropic incompetence (24) and parameters reflecting severe hemodynamic dysfunction  
297 (25, 26) and cardiac dimensions (27, 28) may further improve its predictive capacity and  
298 warrant further investigation.

299

### 300 *Clinical relevance*

301 The observation that non-response to CR training is related to increased all-cause mortality or  
302 hospitalization has important clinical consequences. Independent of baseline fitness levels, the

303 inability to improve fitness after exercise training increases the risk for adverse events.  
304 Especially non-responders with lower baseline fitness are at high risk for adverse events. This  
305 further emphasizes the importance of non-response in CR. Non-modifiable factors (age,  
306 baseline VO<sub>2</sub>-peak) contribute to early identification, which may lead to the prescription of a  
307 different type of CR. For example, non-responders might benefit from other types of exercise  
308 interventions such as high intensity interval training or resistance training to improve their  
309 physical fitness. Literature revealed that HF patient performing high or vigorous intensity  
310 exercise programs have an higher increase in the peak VO<sub>2</sub> compare to moderate intensity  
311 programs (17, 29) and are less likely to show a non-response to training. Resistance exercise  
312 improves muscle mass, strength and muscular fitness in HF patients (30-32) and therefore  
313 might increase cardiovascular fitness by optimizing the response to aerobic conditioning. In  
314 fact, the combination of aerobic and resistance exercise training appeared to be superior for  
315 improving submaximal exercise capacity and health-related quality of life compared to  
316 aerobic exercise only (33). In addition, HF patients who remain to be non-responders, may  
317 have to increase training frequency (34). Such approaches may contribute to a reduction of  
318 future adverse events in this vulnerable group. Finally, strong adherence to exercise training  
319 should be encouraged in HF patients, since adherence is a significant and, more importantly,  
320 modifiable factor for being a non-responder to CR.

321

### 322 *Strengths and limitations*

323 This study included typical HF outpatients, which increases the external validity of our study.  
324 In addition, there were no drop-outs during follow-up which means that all censoring was  
325 non-informative and therefore unrelated to patient prognosis. A limitation of our study may  
326 relate to the exclusion of 17% of eligible HF patients due to an insufficient RER during the  
327 exercise test. However, to guarantee the quality of the achieved maximal VO<sub>2</sub> and thereby the



328 stratification into responder versus non-responder, it was inevitable to exclude those patients.  
329 Furthermore, it was not feasible to use standardized meals before exercise testing. Also, no  
330 data was available about diet or water consumed before the exercise test, which may influence  
331 the VO<sub>2</sub>-peak.

332

### 333 **CONCLUSIONS**

334 Non-responders to exercise training had a 2.15 higher risk of all-cause mortality or unplanned  
335 hospitalization compared with responders after adjustment for possible confounders, a finding  
336 independent from other prognostic markers for adverse events (including baseline levels of  
337 fitness). This observation is of clinical importance since half of the HF patients participating  
338 in a CR-based supervised exercise training program was unable to significantly improve VO<sub>2</sub>-  
339 peak. Higher age and baseline VO<sub>2</sub>-peak, and lower adherence were identified as independent  
340 factors associated with non-response to CR-based exercise training in HF patients.

341 **Acknowledgements**

342 The authors thank Anneke Boot-Krol and Annemiek Huis in 't Veld for data collection and  
343 data entry.

344

345 **Financial support**

346 D.H.J.T. is financially supported by the Netherlands Heart Foundation (E Dekker 2009T064).

347 The work of T.M.H.E is supported by a European Commission Horizon 2020 grant (Marie  
348 Sklodowska-Curie Fellowship 655502).

349

350 **Conflict of interest disclosure**

351 The authors declare that there is no conflict of interest.

352

353 The results of the study do not constitute endorsement by ACSM and are presented clearly,  
354 honestly, and without fabrication, falsification, or inappropriate data manipulation.

355 **References**

- 356 1. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the  
357 management of heart failure: a report of the American College of Cardiology  
358 Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll*  
359 *Cardiol.* 2013;62(16):e147-239.
- 360 2. McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and  
361 treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis  
362 and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of  
363 Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of  
364 the ESC. *Eur J Heart Fail.* 2012;14(8):803-69.
- 365 3. Arena R, Myers J, Abella J et al. Determining the preferred percent-predicted equation  
366 for peak oxygen consumption in patients with heart failure. *Circ Heart Fail.*  
367 2009;2(2):113-20.
- 368 4. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Jr., Wilson JR. Value of  
369 peak exercise oxygen consumption for optimal timing of cardiac transplantation in  
370 ambulatory patients with heart failure. *Circulation.* 1991;83(3):778-86.
- 371 5. Chase PJ, Kenjale A, Cahalin LP et al. Effects of respiratory exchange ratio on the  
372 prognostic value of peak oxygen consumption and ventilatory efficiency in patients  
373 with systolic heart failure. *JACC Heart Fail.* 2013;1(5):427-32.
- 374 6. Keteyian SJ, Patel M, Kraus WE et al. Variables Measured During Cardiopulmonary  
375 Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure. *J Am*  
376 *Coll Cardiol.* 2016;67(7):780-9.
- 377 7. O'Connor CM, Whellan DJ, Lee KL et al. Efficacy and safety of exercise training in  
378 patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA.*  
379 2009;301(14):1439-50.

- 380 8. Taylor RS, Sagar VA, Davies EJ et al. Exercise-based rehabilitation for heart failure.  
381 *Cochrane Database Syst Rev.* 2014;4:CD003331.
- 382 9. Swank AM, Horton J, Fleg JL et al. Modest increase in peak VO<sub>2</sub> is related to better  
383 clinical outcomes in chronic heart failure patients: results from heart failure and a  
384 controlled trial to investigate outcomes of exercise training. *Circ Heart Fail.*  
385 2012;5(5):579-85.
- 386 10. Tabet JY, Meurin P, Beauvais F et al. Absence of exercise capacity improvement after  
387 exercise training program: a strong prognostic factor in patients with chronic heart  
388 failure. *Circ Heart Fail.* 2008;1(4):220-6.
- 389 11. Green DJ, Eijsvogels T, Bouts YM et al. Exercise training and artery function in  
390 humans: nonresponse and its relationship to cardiovascular risk factors. *J Appl Physiol*  
391 *(1985).* 2014;117(4):345-52.
- 392 12. Keteyian SJ, Brawner CA, Ehrman JK et al. Reproducibility of peak oxygen uptake  
393 and other cardiopulmonary exercise parameters: implications for clinical trials and  
394 clinical practice. *Chest.* 2010;138(4):950-5.
- 395 13. Lachin JM. Introduction to sample size determination and power analysis for clinical  
396 trials. *Control Clin Trials.* 1981;2(2):93-113.
- 397 14. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the  
398 number of events per variable in logistic regression analysis. *J Clin Epidemiol.*  
399 1996;49(12):1373-9.
- 400 15. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic  
401 and Cox regression. *Am J Epidemiol.* 2007;165(6):710-8.
- 402 16. Leifer ES, Brawner CA, Fleg JL et al. Are there negative responders to exercise  
403 training among heart failure patients? *Med Sci Sports Exerc.* 2014;46(2):219-24.

- 404 17. Eijssvogels TM, Molossi S, Lee DC, Emery MS, Thompson PD. Exercise at the  
405 Extremes: The Amount of Exercise to Reduce Cardiovascular Events. *J Am Coll*  
406 *Cardiol.* 2016;67(3):316-29.
- 407 18. Downing J, Balady GJ. The role of exercise training in heart failure. *J Am Coll*  
408 *Cardiol.* 2011;58(6):561-9.
- 409 19. Smart N, Marwick TH. Exercise training for patients with heart failure: a systematic  
410 review of factors that improve mortality and morbidity. *Am J Med.* 2004;116(10):693-  
411 706.
- 412 20. Martinez-Selles M, Doughty RN, Poppe K et al. Gender and survival in patients with  
413 heart failure: interactions with diabetes and aetiology. Results from the MAGGIC  
414 individual patient meta-analysis. *Eur J Heart Fail.* 2012;14(5):473-9.
- 415 21. Uddin J, Zwisler AD, Lewinter C et al. Predictors of exercise capacity following  
416 exercise-based rehabilitation in patients with coronary heart disease and heart failure:  
417 A meta-regression analysis. *Eur J Prev Cardiol.* 2016;23(7):683-93.
- 418 22. Meyer K, Gornandt L, Schwaibold M et al. Predictors of response to exercise training  
419 in severe chronic congestive heart failure. *Am J Cardiol.* 1997;80(1):56-60.
- 420 23. Kemps HM, Schep G, de Vries WR et al. Predicting effects of exercise training in  
421 patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.  
422 *Am J Cardiol.* 2008;102(8):1073-8.
- 423 24. Schmid JP, Zurek M, Saner H. Chronotropic incompetence predicts impaired response  
424 to exercise training in heart failure patients with sinus rhythm. *Eur J Prev Cardiol.*  
425 2013;20(4):585-92.
- 426 25. Wilson JR, Groves J, Rayos G. Circulatory status and response to cardiac  
427 rehabilitation in patients with heart failure. *Circulation.* 1996;94(7):1567-72.

- 428 26. Sullivan MJ, Hawthorne MH. Exercise intolerance in patients with chronic heart  
429 failure. *Prog Cardiovasc Dis.* 1995;38(1):1-22.
- 430 27. Pandey A, Ayers C, Blair SN et al. Cardiac determinants of heterogeneity in fitness  
431 change in response to moderate intensity aerobic exercise training: the DREW study. *J*  
432 *Am Coll Cardiol.* 2015;65(10):1057-8.
- 433 28. Smart N, Haluska B, Jeffriess L, Case C, Marwick TH. Cardiac contributions to  
434 exercise training responses in patients with chronic heart failure: a strain imaging  
435 study. *Echocardiography.* 2006;23(5):376-82.
- 436 29. Ismail H, McFarlane JR, Nojournian AH, Dieberg G, Smart NA. Clinical outcomes  
437 and cardiovascular responses to different exercise training intensities in patients with  
438 heart failure: a systematic review and meta-analysis. *JACC Heart Fail.* 2013;1(6):514-  
439 22.
- 440 30. Lavie CJ, Forman DE, Arena R. Bulking Up Skeletal Muscle to Improve Heart Failure  
441 Prognosis. *JACC Heart Fail.* 2016.
- 442 31. Hulsmann M, Quittan M, Berger R et al. Muscle strength as a predictor of long-term  
443 survival in severe congestive heart failure. *Eur J Heart Fail.* 2004;6(1):101-7.
- 444 32. Churchward-Venne TA, Tieland M, Verdijk LB et al. There Are No Nonresponders to  
445 Resistance-Type Exercise Training in Older Men and Women. *J Am Med Dir Assoc.*  
446 2015;16(5):400-11.
- 447 33. Beckers PJ, Denollet J, Possemiers NM, Wuyts FL, Vrints CJ, Conraads VM.  
448 Combined endurance-resistance training vs. endurance training in patients with  
449 chronic heart failure: a prospective randomized study. *Eur Heart J.* 2008;29(15):1858-  
450 66.
- 451 34. Montero D, Lundby C. Refuting the myth of non-response to exercise training: 'non-  
452 responders' do respond to higher dose of training. *J Physiol.* 2017;595(11):3377-87.

**Table 1.** Characteristics of 155 heart failure patients according to their response to cardiac rehabilitation.

	<b>Responders</b> N=70	<b>Non-responders</b> N= 85	<b>P-value</b>
<i>Patient characteristics</i>			
Age (years)	61 (53–67)	63 (55–71)	.09
Sex (male)	47 (67%)	69 (81%)	.045
BMI (kg/m <sup>2</sup> )	28 (SD 5.8)	29 (SD 5.0)	.40
Smoking (current)	16 (23%)	16 (19%)	.54
Diabetes mellitus (yes)	12 (17%)	9 (11%)	.24
COPD (yes)	6 (9%)	9 (11%)	.67
Hypertension (yes)	26 (37%)	38 (45%)	.34
<i>Heart failure characteristics</i>			
Aetiology, ischemic	24 (34%)	40 (47%)	.11
Baseline NYHA			.66
I-II	47 (67%)	63 (74%)	
III-IV	16 (23%)	18 (21%)	
Baseline LVEF			.79
worse (<30%)	20 (28%)	21 (25%)	
moderate (30-45%)	14 (20%)	19 (22%)	
reasonable (45-55%)	3 (4%)	3 (4%)	
good (>55%)	18 (26%)	27 (32%)	
Atrium fibrillation (yes)	20 (29%)	27 (32%)	.67

Medication use

ACEI or ARB	64 (93%)	83 (98%)	.15
Beta blocker agent	64 (91%)	75 (88%)	.52
Aldosteron receptor antagonist	14 (20%)	18 (21%)	.86
Loop diuretic	61 (87%)	68 (80%)	.23
Statin	41 (58%)	52 (61%)	.74

Medical devices

ICD-CRT	13 (19%)	22 (25%)	.26
Pacemaker	10 (14%)	16 (19%)	.44
CRT	1 (1%)	1 (1%)	.90
ICD	15 (21%)	19 (22%)	.87

Rehabilitation program

Type of rehabilitation			.36
MIT	64 (91%)	81 (95%)	
HIT	6 (9%)	4 (5%)	
Duration of rehabilitation (weeks)	20 (12-26)	13 (12-26)	.79
Adherence to exercise program (%)*	91 (81-100)	83 (75-96)	.028

Physiological parameters

Baseline VO <sub>2</sub> -peak (ml/min/kg)	15.2 (13.1–18.6)	16.9 (14.1–20.9)	.025
Post VO <sub>2</sub> -peak (ml/min/kg)	18.8 (15.5–21.9)	15.9 (12.8–19.7)	.017
Difference VO <sub>2</sub> -peak(ml/min)	224 (162–359)	-43 (-136–31)	<.001



Baseline max. heart rate (beats/min)	125 (110–143)	127 (109–144)	.98
Post max. heart rate (beats/min)	129 (113–149)	126 (110–139)	.13
Baseline max. cycle load (Watt)	107 (77–142)	116 (89–149)	.08
Post max. cycle load (Watt)	130 (87–165)	120 (88–150)	.35
Baseline RER	1.16 (1.09–1.22)	1.16 (1.08–1.25)	.90
Post RER	1.15 (1.08–1.22)	1.17 (1.09–1.25)	.22


---

Data is presented in n (%) unless indicated as mean (SD) and median (Q<sub>25</sub>–Q<sub>75</sub>).

\*Data was only available in 135 patients.

BMI = body mass index, COPD = chronic obstructive pulmonary disease, NYHA = New York Heart Association functional classification, LVEF = left ventricular ejection fraction, ACEI = angiotensin-converting enzyme inhibitor, ARB=angiotensin II receptor blocker, ICD = implantable cardioverter defibrillator, CRT = cardiac resynchronization therapy, MIT= moderate intensity training, HIT=high intensity training, VO<sub>2</sub>-peak = peak oxygen consumption max.=maximal and RER=respiratory exchange ratio.


455 **FIGURES**



456

457 **Figure 1.** Flowchart of the inclusion of 155 heart failure patients from Radboud university  
458 medical center and Isala Clinic. The study population consisted of 187 HF patients who met  
459 the inclusion criteria. After inspection for data quality, 32 patients were excluded due to a  
460 maximal respiratory exchange ratio <1.00 during the exercise test. The final study population  
461 comprised 70 responders and 85 non-responders.

462




<b>Non-responders</b>	79	64	39	30	19	9
Responders	64	58	36	30	20	10

463


464 **Figure 2.** Kaplan-Meier curves of the time to death or unplanned hospitalization in 143 heart  
 465 failure patients. In total 57 HF patients were hospitalized or died during follow-up: 36 non-  
 466 responders (46%) and 21 responders (33%). The crude 5-year probability for all-cause  
 467 mortality or unplanned hospitalization was 41% for responders and 56% for non-responders  
 468 (log-rank test  $P=.12$ ).

469



470

471 **Figure 3.** Hazard ratios of all-cause mortality or unplanned hospitalization by baseline fitness  
 472 levels and response to CR. The dots present hazard ratios (95% confidence intervals). Higher  
 473 fitness was defined as baseline  $VO_2$ -peak  $>16.5$  ml/min/kg and lower fitness as  $VO_2$ -peak  
 474  $\leq 16.5$  ml/min/kg. Hazard ratios were adjusted for age, sex and BMI.



475

476 **Figure 4.** Discriminative performance of the prediction model for non-response to exercise  
477 training. The prediction model included age, baseline peak-VO<sub>2</sub> and adherence to the exercise  
478 program. The receiver operating characteristic curve had an area under the curve of 0.73 (95%  
479 CI = 0.65–0.82).

480

**Supplemental Table 1.** Predictors of non-response to exercise training in 155 heart failure patients using univariate logistic regression.

<b>Parameters</b>	<b>Odds ratio</b>	<b>95% CI</b>	<b>P-value</b>
<i>Patient characteristics</i>			
Age (median, years)	1.03	1.00-1.05	.07
Sex (male)	0.47	1.01-4.41	.05
BMI (kg/m <sup>2</sup> )	1.03	0.97-1.09	.40
Smoking (current)	0.78	0.34-1.71	.54
Diabetes mellitus (yes)	0.57	0.23-1.45	.24
COPD (yes)	1.26	0.43-3.74	.67
Hypertension (yes)	1.37	0.72-2.61	.34
<i>Heart failure characteristics</i>			
Aetiology, ischemic	1.70	0.89-3.27	.11
Baseline NYHA (I-II)	1.19	0.55-2.58	.66
Baseline LVEF			
worse (<30%)	0.70	0.30-1.65	.41
moderate (30-45%)	0.91	0.36-2.25	.83
reasonable (45-55%)	0.67	0.12-3.68	.64
good (>55%)	REF		
Atrium fibrillation (yes)	1.16	0.58-2.32	.67
<i>Medication use</i>			

ACEI or ARB	3.24	0.61-17.25	.17
Beta blocker agents	0.58	0.19-1.80	.35
Aldosteron receptor antagonist	1.06	0.48-2.31	.89
Loop diuretics	0.53	0.21-1.30	.16
Statins	1.07	0.56-2.06	.83
<i><u>Medical devices</u></i>			
ICD-CRT	1.55	0.72-3.38	.27
Pacemaker	1.71	0.89-3.28	.11
CRT	1.51	0.71-3.22	.29
ICD	1.46	0.77-2.79	.25
<i><u>Rehabilitation program</u></i>			
Type of rehabilitation*			
MIT	1.90	0.51-7.01	.34
HIT	REF		
Duration of rehabilitation (weeks)	0.99	0.95-1.04	.76
Adherence to exercise program (%)†	0.98	0.97-1.00	.06
<i><u>Physiological parameters</u></i>			
Baseline VO <sub>2</sub> -peak (ml/min/kg)	1.07	1.01-1.14	.03
Baseline max. heart rate (beats/min)‡	1.00	0.99-1.01	.91
Baseline max. cycle load (Watt)‡	1.01	0.99-1.01	.07

---

\*excluded in multivariable model due to low numbers.

†data was only available in 135 patients.


‡excluded in multivariable model due to high correlation with VO<sub>2</sub>-peak.

BMI = body mass index, COPD = chronic obstructive pulmonary disease, NYHA= New York Heart Association classification, LVEF = left ventricular ejection fraction, ACEI = angiotensin-converting enzyme inhibitor, ARB=angiotensin II receptor blocker, ICD = implantable cardioverter defibrillator, CRT = cardiac resynchronization therapy, MIT= moderate intensity training, HIT=high intensity training, REF= reference, VO<sub>2</sub>-peak = peak oxygen consumption, max.= maximal and RER=respiratory exchange ratio.

483

484 **Supplemental Figure 1.** Relative difference in VO<sub>2</sub>-peak (%) between baseline and post  
485 exercise training values. Responders are presented in dark grey and non-responders in light  
486 grey. The dashed line represents a 6% improvement in VO<sub>2</sub>-peak, which was the cut-point for  
487 being a responder or non-responder.

488



489